New pentamidine related substances which simultaneously inhibit platelet aggregation and accelerate plasmin generation and in vitro clot lysis.
Pentamidine, a highly toxic drug, possesses RGD-peptide (Arg-Gly-Asp)-like antiplatelet actions. The objective of this investigation was to study the anticipated profibrinolytic and antiplatelet actions of pentamidine and of pentamidine (bearing guanidino-like groups)-related synthetic peptidomimetic compounds. Platelet aggregation inhibition was assessed using ADP, thrombin, collagen, arachidonic acid and epinephrine as inducers, by aggregometry. In vitro chromogenic plasmin generation tests and clot lysis assays were also performed. Two (assigned as D-2 and D-3) of the synthetic pentamidine-guanidino related molecules were able to inhibit platelet aggregation and simultaneously accelerate in vitro plasmin generation and clot-lysis in the nM range. These dual action antithrombotic agents now need to be tested further to assess their antithrombotic actions in vivo.
Udvardy
M
M
2nd Department of Medicine, Debrecen University Medical School, Hungary.
Posan
E
E
Harsfalvi
J
J
Dinya
Z
Z
D001777:Blood Coagulation; D005337:Fibrin / Q000378:metabolism; D005341:Fibrinolysin / Q000096:biosynthesis*; D006801:Humans; D066298:In Vitro Techniques; D009842:Oligopeptides; D010419:Pentamidine / Q000031:analogs & derivatives / Q000494:pharmacology*; D010974:Platelet Aggregation / Q000187:drug effects*
D009842:Oligopeptides; D010419:Pentamidine; C047981:arginyl-glycyl-aspartic acid; D005337:Fibrin; D005341:Fibrinolysin